WCM Investment Management LLC cut its holdings in Natus Medical Inc (NASDAQ:BABY) by 2.9% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 391,646 shares of the medical equipment provider’s stock after selling 11,537 shares during the period. WCM Investment Management LLC owned 1.15% of Natus Medical worth $10,061,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Alambic Investment Management L.P. bought a new stake in Natus Medical in the 1st quarter worth $1,207,000. Norges Bank bought a new stake in Natus Medical in the 4th quarter worth $11,884,000. Martingale Asset Management L P grew its holdings in Natus Medical by 547.4% in the 1st quarter. Martingale Asset Management L P now owns 141,823 shares of the medical equipment provider’s stock worth $3,601,000 after acquiring an additional 119,918 shares during the last quarter. Strs Ohio grew its holdings in Natus Medical by 6.8% in the 2nd quarter. Strs Ohio now owns 141,000 shares of the medical equipment provider’s stock worth $3,622,000 after acquiring an additional 9,000 shares during the last quarter. Finally, MERIAN GLOBAL INVESTORS UK Ltd bought a new stake in Natus Medical in the 1st quarter worth $706,000. Institutional investors and hedge funds own 91.56% of the company’s stock.

Shares of BABY remained flat at $$26.75 during trading hours on Thursday. Natus Medical Inc has a 52-week low of $23.53 and a 52-week high of $37.90. The firm has a market cap of $909.77 million, a PE ratio of 18.84 and a beta of 0.57. The firm has a 50-day moving average of $28.34 and a 200 day moving average of $26.87. The company has a current ratio of 1.70, a quick ratio of 1.18 and a debt-to-equity ratio of 0.18.

Natus Medical (NASDAQ:BABY) last issued its quarterly earnings results on Thursday, July 25th. The medical equipment provider reported $0.34 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.30 by $0.04. Natus Medical had a negative net margin of 7.38% and a positive return on equity of 10.79%. The company had revenue of $125.50 million during the quarter, compared to analysts’ expectations of $122.85 million. During the same period last year, the company posted $0.35 EPS. Natus Medical’s revenue was down 4.0% on a year-over-year basis. Sell-side analysts anticipate that Natus Medical Inc will post 1.27 EPS for the current year.

In other news, Director Ken Ludlum sold 4,250 shares of the business’s stock in a transaction that occurred on Tuesday, June 11th. The shares were sold at an average price of $24.41, for a total transaction of $103,742.50. Following the completion of the transaction, the director now directly owns 46,192 shares of the company’s stock, valued at $1,127,546.72. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Austin Francis Noll III sold 20,000 shares of the business’s stock in a transaction that occurred on Wednesday, July 31st. The shares were sold at an average price of $31.14, for a total transaction of $622,800.00. Following the transaction, the vice president now directly owns 105,193 shares of the company’s stock, valued at $3,275,710.02. The disclosure for this sale can be found here. Insiders sold 42,882 shares of company stock valued at $1,279,049 over the last ninety days. Corporate insiders own 1.65% of the company’s stock.

A number of equities research analysts have issued reports on BABY shares. TheStreet lowered shares of Natus Medical from a “c-” rating to a “d+” rating in a report on Thursday, April 25th. BidaskClub raised shares of Natus Medical from a “strong sell” rating to a “sell” rating in a research note on Tuesday, July 23rd. ValuEngine lowered shares of Natus Medical from a “hold” rating to a “sell” rating in a research note on Wednesday, May 1st. Finally, Zacks Investment Research raised shares of Natus Medical from a “strong sell” rating to a “hold” rating in a research note on Wednesday, June 26th. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating and one has issued a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average target price of $36.00.

About Natus Medical

Natus Medical Incorporated provides neurology, newborn care, and hearing and balance assessment healthcare products and services worldwide. It offers products and services used for the screening, diagnosis, detection, treatment, monitoring, and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction and neurosurgical treatments, epilepsy, sleep disorders, neuromuscular diseases, and balance and mobility disorders.

Featured Story: Example of operating income, EBIT and EBITDA

Want to see what other hedge funds are holding BABY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Natus Medical Inc (NASDAQ:BABY).

Institutional Ownership by Quarter for Natus Medical (NASDAQ:BABY)

Receive News & Ratings for Natus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natus Medical and related companies with MarketBeat.com's FREE daily email newsletter.